Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-05-11T19:42:34.761Z Has data issue: false hasContentIssue false
  • English
  • Français

Major Depressive Disorder: Epidemiology, Course of Illness, and Treatment

Published online by Cambridge University Press:  07 November 2014

Andrew A. Nierenberg
Get access Rights & Permissions [Opens in a new window]

Extract

Understanding the epidemiology of major depressive disorder (MDD) and the neurobiologic theories behind depression and antidepressant treatment is vital for physicians who must identify and treat patients with this disorder. The epidemiology of MDD reveals that this disorder is widespread: the lifetime prevalence of MDD is estimated to be ∼17% and the 12-month prevalence is ≥7%, according to the National Comorbidity Survey Replication. Epidemiologic studies suggest that in any 30-day period, 2% to 5% of the United States population meet criteria for MDD. In addition, nearly twice as many women as men (21% versus 13%, respectively) are affected by a depressive disorder during their lifetimes. These numbers reveal a vast population of people affected by MDD, making depression a tremendous social and medical concern.

Type
Expert Roundtable Supplement
Information
CNS Spectrums , Volume 13 , Issue S8: Adult Attention-Deficit/Hyperactivity Disorder and the Role of Depression , May 2008 , pp. 4 - 7
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Blazer, DG, Kessler, RC, McGonagle, KA, Swartz, MS.The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994;151(2):979–986.Google Scholar
2.Kessler, RC, McGonagle, KA, Swartz, M, Blazer, DG, Nelson, CB.Sex and depression in the National Comorbidity Survey I: Lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29(2–3):85–96.CrossRefGoogle ScholarPubMed
3.Regier, DA, Boyd, JH, Burke, JD Jr, et al. One-month prevalence of mental disorders in the United States: based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45(11):977–986.CrossRefGoogle ScholarPubMed
4.Murray, CJL. Rethinking Dalys. In: Murray, CJL, Lopez, AD, eds. The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Ma: Harvard University Press and the World Health Organization; 1996:6–43.Google Scholar
5.Greenberg, PE, Stiglin, LE, Finkelstein, SN, Berndt, ER.The economic burden of depression in 1990. J Clin Psychiatry. 1993;54(11):405–418.Google ScholarPubMed
6.Kessler, RC, Berglund, P, Demler, O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105.CrossRefGoogle ScholarPubMed
7.Shelton, RC.The molecular biology of depression. Psychiatr Clin North Am. 2007;30(1):1–11.CrossRefGoogle Scholar
8.Hasler, G, Drevets, WC, Manji, HK, Charney, DS.Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29(10):1765–1781.CrossRefGoogle ScholarPubMed
9.Duman, RS.Depression: a case of neuronal life and death? Biol Psychiatry. 2004;56(3):140–145.CrossRefGoogle ScholarPubMed
10.Sahay, A, Hen, R.Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007;10(9):1110–1115.CrossRefGoogle ScholarPubMed
11.Caspi, A, Sugden, K, Moffitt, TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386–389.CrossRefGoogle ScholarPubMed
12.Pezawas, L, Meyer-Lindenberg, A, Drabant, EM, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci. 2005;8(6):828–834.CrossRefGoogle ScholarPubMed
13.Hariri, AR, Drabant, EM, Munoz, KE, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry. 2005;62(2):146–152.CrossRefGoogle ScholarPubMed
14.Johnstone, T, van Reekum, CM, Urry, HL, Kalin, NH, Davidson, RJ.Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression. J Neurosci. 2007;27(33):8877–8884.CrossRefGoogle ScholarPubMed
15.Pezawas, L, Meyer-Lindenberg, A, Goldman, AL, et al. Evidence of biological epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry. In press.Google Scholar
16.Kupfer, DJ.Long-term treatment of depression. J Clin Psychiatry. 1991;52(suppl 5):28–34.Google ScholarPubMed
17.Lavori, PW, Keller, MB, Mueller, TI, Scheftner, W.Recurrence after recovery in unipolar MDD: an observational follow-up study of clinical predictors and somatic treatment as a mediating factor. Int J Meth Psychiatr Res. 1994;4:211–229.Google Scholar
18.McManus, P, Mant, A, Mitchell, P, Dudley, J.Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia. Aust N Z J Psychiatry. 2004;38(6):450–454.CrossRefGoogle ScholarPubMed
19.Fava, GA, Rafanelli, C, Grandi, S, Canestrari, R, Morphy, MA.Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1998;155(10):1443–1445.CrossRefGoogle ScholarPubMed
20.Fava, GA, Ruini, C, Rafanelli, C, Finos, L, Conti, S, Grandi, S.Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry. 2004;161(10):1872–1876.CrossRefGoogle ScholarPubMed
21.Rush, AJ, Trivedi, M, Fava, M.Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry. 2003;160(2):237.CrossRefGoogle ScholarPubMed
22.Trivedi, MH, Rush, AJ, Wisniewski, SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.CrossRefGoogle ScholarPubMed
23.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–1242.CrossRefGoogle ScholarPubMed
24.Trivedi, MH, Fava, M, Wisniewski, SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243–1252.CrossRefGoogle ScholarPubMed
25.Fava, M, Rush, AJ, Wisniewski, SR, et al. A comparison of mirtazapine and nor-triptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163(7):1161–1172.CrossRefGoogle Scholar
26.Nierenberg, AA, Fava, M, Trivedi, MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519–1530.CrossRefGoogle Scholar
27.McGrath, PJ, Stewart, JW, Fava, M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531–1541.CrossRefGoogle ScholarPubMed